Gilead Sciences is already preparing the supply architecture for a once-yearly HIV prevention medicine that has not yet completed its pivotal Phase 3 program, extending six royalty-free voluntary licensing agreements for lenacapavir to manufacturers serving 120 high-incidence, predominantly low- and lower-middle-income countries. The September 16 move is strategically significant because Gilead is attempting to remove one of the recurring bottlenecks in global HIV innovation: the long delay between regulatory approval of a major prevention technology and meaningful access in countries carrying much of the disease burden.
The expanded agreements cover the investigational once-yearly formulation being evaluated in the Phase 3 PURPOSE 365 trial. They build on licensing arrangements surrounding Gilead’s longer-acting lenacapavir strategy and allow partners to begin manufacturing readiness, technology transfer and future supply planning before PURPOSE 365 results and potential regulatory decisions. Gilead has therefore chosen to incur preparation risk ahead of clinical certainty, rather than waiting for the study to succeed before beginning the lengthy work of establishing distributed supply.
That decision reflects how commercially and clinically important the dosing interval could become. HIV pre-exposure prophylaxis is highly effective when taken as intended, but adherence has always been one of the central challenges of prevention. Moving from daily tablets, or even less-frequent injectable schedules, toward a medicine potentially administered only once a year could materially alter how prevention programs are designed.
Why could once-yearly PrEP change the HIV prevention market?
The most obvious advantage is adherence. A patient prescribed daily oral prevention must maintain protection through hundreds of individual dosing decisions every year. Long-acting injectable PrEP reduces that burden substantially, but even twice-yearly or more frequent clinic visits require healthcare access, appointment adherence and delivery infrastructure.
A once-yearly intervention would compress that behavioral burden dramatically. One successful administration could potentially provide an extended period of prevention without requiring the patient to remember daily tablets or repeatedly return to a clinic. The practical value could be particularly high among populations facing stigma, unstable housing, transportation barriers or inconsistent access to healthcare.
The opportunity also carries substantial public-health significance because prevention works only when people can obtain and continue using it. A technologically impressive PrEP option that reaches only affluent markets would leave much of the global disease burden unchanged. Gilead’s decision to prepare generic manufacturing capacity before approval therefore addresses the distribution question alongside the clinical one.
The commercial equation is more complicated. Voluntary licensing means Gilead will not capture the same economics in 120 resource-limited countries that it could command in higher-income markets. However, broad access can increase treatment scale, reinforce lenacapavir as a global HIV platform and reduce political pressure around affordability. For a company with decades of HIV leadership, access strategy is also inseparable from franchise credibility.
What must PURPOSE 365 prove before this strategy becomes real?
PURPOSE 365 remains the crucial clinical gatekeeper. Manufacturing readiness does not mean the investigational regimen has been proven safe and effective, and Gilead has explicitly positioned the licensing expansion ahead of Phase 3 results and regulatory approvals.
A yearly formulation raises questions beyond whether drug concentrations remain detectable. Regulators will need confidence that protection remains adequate throughout the entire interval, including toward the end of the dosing period. Safety is equally important because a very long-acting medicine cannot simply be removed from the body if an adverse reaction occurs.
Drug resistance will also be closely watched. Long pharmacokinetic tails can become relevant if concentrations gradually fall below protective levels while remaining sufficient to exert selective pressure on HIV. Prevention programs will therefore need clear guidance around HIV testing, delayed injections and management of patients who acquire infection despite prophylaxis.
If PURPOSE 365 succeeds on those dimensions, however, the formulation could become one of the most differentiated products in the HIV prevention field.
Why is lenacapavir strategically important to Gilead Sciences?
Few large pharmaceutical companies are as closely identified with one therapeutic category as Gilead Sciences is with HIV. The company built major franchises around antiretroviral treatment and has subsequently sought to extend that leadership into prevention and longer-acting medicines.
Lenacapavir is central to that transition because its long duration creates opportunities that conventional daily therapies cannot easily match. Successful expansion into prevention could give Gilead a platform spanning treatment and prophylaxis while creating an important lifecycle around different dosing intervals and patient populations.
The strategy is also defensive. HIV treatment has become increasingly competitive, and older medicines inevitably face patent erosion. Sustaining Gilead’s position therefore requires new formulations and mechanisms capable of resetting the competitive landscape rather than merely replacing one daily tablet with another.
A once-yearly product could accomplish that if the clinical profile proves sufficiently strong. It would compete not simply on efficacy but on convenience, adherence and healthcare-system workflow.
Why is manufacturing being addressed before regulatory approval?
Pharmaceutical manufacturing scale-up can take years, particularly when technology transfer involves multiple producers and regulatory jurisdictions. Waiting for an FDA or other regulatory approval before starting that process would risk creating a large interval in which wealthy countries receive a new prevention option while high-burden countries wait for supply.
Gilead’s licensing structure attempts to compress that lag. The six manufacturers can undertake technical work while PURPOSE 365 progresses, giving them a better chance of supplying eligible countries relatively quickly if the product is eventually cleared.
There is obvious risk. If PURPOSE 365 fails, some preparatory work will not translate into a commercial product. Gilead appears willing to accept that risk because the cost of waiting could be measured not merely in lost sales but in delayed population-level prevention.
This is an important distinction in interpreting the announcement. It is not a regulatory milestone and should not be treated as evidence that once-yearly lenacapavir works. It is an infrastructure milestone designed to make successful clinical results more actionable if they arrive.
What happens next for Gilead’s once-yearly PrEP strategy?
Everything ultimately returns to PURPOSE 365. The clinical results will determine whether the convenience proposition has a viable medicine behind it, and regulators will then scrutinize efficacy, safety, pharmacokinetics and implementation.
If those pieces align, the competitive question becomes particularly interesting. HIV prevention could develop into a market where patients choose among daily oral medicines, longer-acting injectables and potentially annual administration. Convenience could become almost as important as conventional pharmaceutical differentiation.
The 120-country licensing footprint would then give Gilead a mechanism for expanding access while preserving a branded commercial opportunity in wealthier markets. That combination could prove unusually powerful because infectious-disease products often derive strategic value from scale that extends beyond conventional per-patient revenue.
For now, Gilead is doing something uncommon in pharmaceutical development: preparing for global access before knowing whether the pivotal trial will succeed. The bet is that if once-yearly lenacapavir works, losing years to manufacturing preparation would be the more expensive mistake.
